POCI

POCI is a sub-$40M optics maker that has lost money every year on record (FY21–FY25) and is now losing more, not less: net income deteriorated to -$5.78M in FY2025 from -$2.95M in FY2024 (-95.8% YoY), and gross margin cratered from 30.3% to 17.8%. Management attributes the gross-profit collapse (down 41.3% to $3.40M) to 'yield issues associated with new manufacturing lines' and lower billable-engineering utilization as the single-use cystoscope program shifted from Engineering Design Services (revenue -42%) into Systems Manufacturing (+122%). That mix shift kept total revenue flat at $19.1M (-0.1%) but converted profitable design work into low-yield, scaling manufacturing — the reason profitability got worse while the top line stood still.

The binding problem is liquidity. Cash is just $1.77M against operating cash outflow of -$3.55M in FY2025, i.e. well under a year of runway at the current burn. The 10-K itself flags that the company 'must generate sufficient cash flow or raise additional capital' and may 'curtail our research and development initiatives' if capital is unavailable. Share count already rose 21.5% YoY to 7.71M — dilution is underway — and any raise near a $5 stock with a -$57.0M accumulated deficit and -47.2% ROE would be dilutive to existing holders. The balance sheet is not levered (liabilities/equity 0.61x, equity $12.3M), but equity is heavily intangible/working-capital driven and the cash line is the constraint that matters.